Identification of SARS-CoV RBD-targeting monoclonal antibodies with cross-reactive or neutralizing activity against SARS-CoV-2. – Research Polyclonal and Monoclonal antibodies

Read more about the article Identification of SARS-CoV RBD-targeting monoclonal antibodies with cross-reactive or neutralizing activity against SARS-CoV-2.

Identification of SARS-CoV RBD-targeting monoclonal antibodies with cross-reactive or neutralizing activity against SARS-CoV-2.

Post author:Joanne Kennedy
Post published:May 18, 2020
Post category:Identification of SARS-CoV RBD-targeting monoclonal antibodies with cross-reactive or neutralizing activity against SARS-CoV-2.

SARS-CoV-2-caused COVID-19 instances are rising globally, calling for growing efficient therapeutics to regulate the present pandemic. SARS-CoV-2 and SARS-CoV acknowledge angiotensin-converting enzyme 2 (ACE2) receptor through the receptor-binding area (RBD).…